Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer

BET inhibitors are promising therapeutic agents for the treatment of triple-negative breast cancer (TNBC), but the rapid emergence of resistance necessitates investigation of combination therapies and their effects on tumor evolution. Here, we show that palbociclib, a CDK4/6 inhibitor, and paclitaxe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Ge, Jennifer Y., Shu, Shaokun, Kwon, Mijung, Jovanović, Bojana, Murphy, Katherine, Gulvady, Anushree, Fassl, Anne, Trinh, Anne, Kuang, Yanan, Heavey, Grace A., Luoma, Adrienne, Paweletz, Cloud, Thorner, Aaron R., Wucherpfennig, Kai W., Qi, Jun, Brown, Myles, Sicinski, Piotr, McDonald, Thomas O., Pellman, David, Michor, Franziska, Polyak, Kornelia
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7214447/
https://ncbi.nlm.nih.gov/pubmed/32393766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-16170-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados